Real-World Studies
youngAMBORA Mitigates Medication Errors in Paediatric Oral Antitumour Therapy
Lensker et alBritish Journal of Clinical Pharmacology
Oral antitumour therapeutics (OAT) offer substantial clinical convenience in paediatric oncology but introduce complex, error-prone administration challenges in outpatient settings. To address these vulnerabilities, investigators adapted the adult AMBORA trial framework to create youngAMBORA—a structured, pharmacological and pharmaceutical care program tailored to paediatric patients and their caregivers. The study evaluated the clinical impact of this model on medication safety by evaluating patient-reported outcomes (PROs) alongside systematic medication error tracking.
The intervention involved three or four dedicated consultation sessions initiated at therapy onset (Week 0), incorporating specialized educational materials, advanced medication reviews at each visit, and validated assessment tools. Patient-reported knowledge was measured using the Satisfaction with Information about Medicines Scale (SIMS) as the primary outcome, while toxicity was captured via Ped-PRO-CTCAE. Medication discrepancies and administration issues were systematically categorized using the PCNE V9.1 classification system.
The study included 54 paediatric patients undergoing therapy with 61 OAT regimens, most commonly 6-mercaptopurine (23%; 14/61). Patient and caregiver knowledge improved rapidly following program initiation, reflected in a doubling of the SIMS score from Week 0 to Week 1 (8.1 ± 4.2 vs. 15.8 ± 1.6; p < .0001). Across the cohort, an average of 2.6 treatment-related adverse effects were reported per patient, with nausea and other gastrointestinal toxicities emerging as the most prevalent and severe.
Crucially, the medication review process detected 56 OAT-related medication errors (averaging 1.0 error per patient). Through targeted clinical interventions during consultations, 84% (47/56) of these errors were completely resolved. These findings demonstrate that structured pharmaceutical care protocols optimize medication safety during paediatric oral oncology treatment by rapidly closing caregiver knowledge gaps, tracking symptomatic toxicities, and rectifying potentially harmful dosing and administration errors.
Key Takeaways
- Medication knowledge among patients and caregivers significantly improved within one week of initiating the youngAMBORA program, with Satisfaction with Information about Medicines Scale (SIMS) scores increasing from 8.1 ± 4.2 at baseline to 15.8 ± 1.6 at Week 1 (p < .0001).
- The clinical care program identified 56 oral antitumour therapy-related medication errors across 54 patients (mean 1.0 per patient), achieving complete resolution in 84% (47/56) of identified errors through advanced medication reviews.
- Patients and caregivers documented an average of 2.6 treatment-related adverse effects per patient, with gastrointestinal symptoms, predominantly nausea, identified as the most frequent and severe toxicities.
Read the original sourceBritish Journal of Clinical Pharmacology
